{"id":487493,"date":"2021-05-05T07:03:31","date_gmt":"2021-05-05T11:03:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrate-that-99-of-surveyed-patients-diagnosed-with-uveal-melanoma-gain-value-from-decisiondx-um-test\/"},"modified":"2021-05-05T07:03:31","modified_gmt":"2021-05-05T11:03:31","slug":"new-data-demonstrate-that-99-of-surveyed-patients-diagnosed-with-uveal-melanoma-gain-value-from-decisiondx-um-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrate-that-99-of-surveyed-patients-diagnosed-with-uveal-melanoma-gain-value-from-decisiondx-um-test\/","title":{"rendered":"New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test"},"content":{"rendered":"

<\/p>\n

New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test <\/b><\/p>\n

Study Also Shows that Patients\u2019 Decision Regret Levels Do Not Vary According To Low- Or High-Risk DecisionDx-UM Test Result<\/i><\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE<\/a>)–
\nCastle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented data on its 15-gene expression profile (15-GEP) test, DecisionDx\u00ae<\/sup>-UM, at the Association for Research in Vision and Ophthalmology (ARVO) 2021: Revolutionary Eye and Vision Research Meeting.\n<\/p>\n

\nThe virtual poster is entitled \u201cUveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling.\u201d\n<\/p>\n

\nDecisionDx-UM, the test highlighted in the poster, is Castle\u2019s prognostic 15-GEP test for patients with uveal melanoma, a rare cancer of the eye that carries a high risk of spreading (metastasizing). The DecisionDx-UM test is designed to accurately identify patients who are at low risk (Class 1) or high risk (Class 2) of metastasis based on the unique biology of their primary tumor and is the current standard of care in the management of uveal melanoma at the majority of U.S. ocular oncology practices.\n<\/p>\n

\n\u201cUp to half of patients diagnosed with uveal melanoma will experience metastatic disease, and prior studies show that newly diagnosed patients have overwhelmingly been in favor of learning their prognoses,\u201d said first author Basil K. Williams, M.D., assistant professor and director of Ocular Oncology at the University of Cincinnati College of Medicine. \u201cThis study demonstrated that uveal melanoma patients were satisfied with their decisions to pursue prognostic information through GEP testing, and they found particular value in DecisionDx-UM\u2019s ability to help them understand their individual metastatic risk.\u201d\n<\/p>\n

Study methods and findings:<\/i><\/p>\n